Lacosamide Hikma

Lacosamide, the active ingredient in Lacosamide Hikma, is an anticonvulsant presented as a intravenous solution for intravenous use. It treats partial‑onset seizures and is used as adjunctive therapy for epilepsy in patients who require additional seizure control.

GNH USA supplies Lacosamide Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant indicated for seizure disorders.

- Partial‑onset seizures: Reduces seizure frequency when added to existing antiepileptic regimens. - Adjunctive therapy for epilepsy: Provides additional seizure control in patients not fully managed by other medications. - Focal seizures (including secondary generalization): Helps control seizures that originate from a focal brain region.

Adverse reactions have been reported with intravenous lacosamide.

Common Side Effects: - Dizziness - Nausea - Fatigue - Headache

Serious or Rare Side Effects: - Cardiac arrhythmias (e.g., PR‑interval prolongation) - Severe skin reactions such as Stevens‑Johnson syndrome - Respiratory depression

Use of Lacosamide Hikma requires careful clinical assessment. - Renal impairment: Monitor renal function and adjust therapy as needed. - Hepatic impairment: Use with caution; consider liver function monitoring. - Cardiac conduction disorders: Obtain baseline ECG and observe for PR‑interval changes. - Concomitant CNS depressants: May increase sedation; monitor patient responsiveness. - Pregnancy: Safety not established; weigh potential benefits against risks. - Store at 2‑8°C: Keep refrigerated, protect from light, do not freeze or shake.

Lacosamide may interact with several medications.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase lacosamide levels. - Strong CYP3A4 inducers (e.g., carbamazepine): May reduce lacosamide exposure. - Other sodium‑channel blockers (e.g., phenytoin): Additive effect on neuronal excitability. - Drugs that prolong PR interval (e.g., beta‑blockers): Risk of cardiac conduction delay.

Moderate Interactions (Monitor Closely): - Oral contraceptives: May reduce hormonal efficacy. - Alcohol: Potentially enhanced CNS depression. - Antiplatelet agents: Observe for increased bleeding tendency.